Exicure Profit Margin 2017-2021 | XCUR

Current and historical gross margin, operating margin and net profit margin for Exicure (XCUR) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Exicure net profit margin as of June 30, 2021 is -1318.75%.
Exicure Annual Profit Margins
Exicure Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.101B $0.017B
Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76